Anti-Müllerian Hormone Concentrations Are Inversely Associated With Subclinical Atherosclerosis in Premenopausal Women
Abstract
Anti-Müllerian hormone (AMH), which is secreted by granulosa cells of late preantral and small antral follicles, is a marker of ovarian reserve. The association of ovarian reserve with subclinical atherosclerosis in women of reproductive age is currently unknown. We primary investigated whether AMH levels are associated with markers of subclinical atherosclerosis in healthy, normally menstruating women. In this cross-sectional study, vascular structure and function were assessed by measurement of carotid and femoral intima–media thickness (IMT), flow-mediated dilation, carotid–femoral pulse wave velocity and augmentation index. Lipid profile and serum AMH concentrations were also measured. Seventy premenopausal women, aged 32.7 ± 6.5 years, were included. Mean AMH levels were lower in smokers than in non-smokers and negatively associated with total cholesterol (TC) levels. An inverse association between mean AMH concentrations and femoral and carotid IMT in all segments was observed. No correlation with other markers of subclinical atherosclerosis or established cardiovascular (CV) risk factors was found. After multivariable adjustment, the association between AMH concentrations and combined carotid IMT or carotid bulb IMT remained significant. In conclusion, in healthy, normally ovulating women, AMH concentrations are negatively associated with subclinical atherosclerosis indices and TC levels, independently of established CV risk factors.
Get full access to this article
View all access and purchase options for this article.
References
1. Writing Group Members, Mozaffarian D, Benjamin EJ, et al;. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
2. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118:1273–93.
3. Bruno RM, Bianchini E, Faita F, Taddei S, Ghiadoni L. Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound. 2014;12:34.
4. Lambrinoudaki I, Chatzivasileiou P, Stergiotis S, et al. Subclinical atherosclerosis and vascular stiffness in premenopausal women: association with NOS3 and CYBA polymorphisms. Heart Vessels. 2018;33:1434–44.
5. Ledger WL. Clinical utility of measurement of anti-Müllerian hormone in reproductive endocrinology. J Clin Endocrinol Metab. 2010;95:5144–54.
6. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.
7. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-Müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96:2532–9.
8. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-Müllerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012;97:1673–80.
9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.
10. Stein JH, Korcarz CE, Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement. Prev Cardiol. 2009;12:34–8.
11. Stamatelopoulos K, Georgiopoulos G, Athanasouli F, et al. Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis. Circ Res. 2019;125:744–58.
12. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–25.
13. Stamatelopoulos K, Athanasouli F, Pappa T, et al. Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99:2704–11.
14. O’Rourke MF. Influence of ventricular ejection on the relationship between central aortic and brachial pressure pulse in man. Cardiovasc Res. 1970;4:291–300.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
16. Fotis L, Giannakopoulos D, Stamogiannou L, Xatzipsalti M. Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in children. Do they play a role in the progression of atherosclerosis? Hormones (Athens). 2012;11:140–6.
17. Matuszek MA, Aristoteli LP, Bannon PG, et al. Haptoglobin elutes from human atherosclerotic coronary arteries—a potential marker of arterial pathology. Atherosclerosis. 2003;168:389–96.
18. Rustamov O, Smith A, Roberts SA, et al. The measurement of anti-Müllerian hormone: a critical appraisal. J Clin Endocrinol Metab. 2014;99:723–32.
19. Appt SE, Chen H, Clarkson TB, Kaplan JR. Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis. Menopause. 2012;19:1353–9.
20. De Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, van der Schouw YT. Anti-Müllerian hormone trajectories are associated with cardiovascular disease in women: results from the Doetinchem Cohort Study. Circulation. 2017;135:556–65.
21. Ramezani Tehrani F, Montazeri SA, Khalili D, et al. Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease. Climacteric. 2016;19:344–8.
22. Yarde F, Spiering W, Franx A, et al. Association between vascular health and ovarian ageing in type 1 diabetes mellitus. Hum Reprod. 2016;31:1354–62.
23. Kim C, Pan Y, Braffett BH, et al. Anti-Müllerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes. Womens Midlife Health. 2017;3:5.
24. Tehrani FR, Erfani H, Cheraghi L, Tohidi M, Azizi F. Lipid profiles and ovarian reserve status: a longitudinal study. Hum Reprod. 2014;29:2522–9.
25. de Kat AC, Verschuren WM, Eijkemans MJ, van der Schouw YT, Broekmans FJ. The association of low ovarian reserve with cardiovascular disease risk: a cross-sectional population-based study. Hum Reprod. 2016;31:1866–74.
26. Verit FF, Akyol H, Sakar MN. Low antimüllerian hormone levels may be associated with cardiovascular risk markers in women with diminished ovarian reserve. Gynecol Endocrinol. 2016;32:302–5.
27. Anderson EL, Fraser A, McNally W, et al. Anti-Müllerian hormone is not associated with cardiometabolic risk factors in adolescent females. PLoS One. 2013;8:e64510.
28. Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180:41–50.
29. Anagnostis P, Goulis DG. Menopause and its cardiometabolic consequences: current perspectives. Curr Vasc Pharmacol. 2019;17:543–45.
30. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767–76.
31. Sarnowski C, Kavousi M, Isaacs S, et al. Genetic variants associated with earlier age at menopause increase the risk of cardiovascular events in women. Menopause. 2018;25:451–7.
32. Braem MG, Voorhuis M, van der Schouw YT, et al. Interactions between genetic variants in AMH and AMHR2 may modify age at natural menopause. PLoS One. 2013;8:e59819.
33. Kevenaar ME, Themmen AP, Rivadeneira F, et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod. 2007;22:2382–8.
34. Ricci M, Mohapatra B, Urbiztondo A, et al. Differential changes in TGF-beta/BMP signaling pathway in the right ventricular myocardium of newborns with hypoplastic left heart syndrome. J Card Fail. 2010;16:628–34.
35. Dennis NA, Jones GT, Chong YH, van Rij AM, McLennan IS. Serum anti-Müllerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: is AMH a cardiovascular hormone? J Endocrinol. 2013;219:13–20.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: March 25, 2020
Issue published: July 2020
Keywords
PubMed: 32208847
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 258
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 13 view articles Opens in new tab
Crossref: 0
-
Low-serum antimüllerian hormone is linked with poor semen quality in i...
-
Correlation of AMH with Cardiometabolic Markers in Polycystic Ovarian ...
-
Change of HeART: Cardiovascular Implications of Assisted Reproductive ...
-
Anti-Mullerian hormone and cardiometabolic status: a systematic review
-
Does the addition of serum antimüllerian hormone concentrations to the...
-
The independent associations of anti-Müllerian hormone and estradiol l...
-
The Effect of Gastric Sleeve Resection on Menstrual Pattern and Ovulat...
-
Anti‐Müllerian hormone and vascular dysfunction in women with chronic ...
-
Outdoor air pollution and diminished ovarian reserve among infertile K...
-
Decline in anti-Müllerian hormone concentrations following radioactive...
-
Serum anti-Mullerian hormone, prolactin and estradiol concentrations i...
-
Importance of Sensitive Vascular Measurements for Evaluating Effects o...
-
Breastfeeding is associated with lower subclinical atherosclerosis in ...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
